Skip to main content
. Author manuscript; available in PMC: 2020 Jul 1.
Published in final edited form as: Brain Behav Immun. 2019 Jan 31;79:174–185. doi: 10.1016/j.bbi.2019.01.028

Figure 9.

Figure 9.

Quantitation of Western blot data of Figure 7. The expression of endogenous IFN-α increased significantly in all treatment groups (A1, B1 and C1). IFNAR siRNA significantly decreased p-IFNAR, IFNAR (A2), p-JAK1 (A3), p-STAT1 (A4) and TRAF3 (A5) expression, which was accompanied by an increase of p-NF-κB (A6), IL-6 (A7) and TNF-α (A8) 3 days after GMH. p-JAK1 (B3) was declined significantly by ruxolitinib 3 days after intraperitoneal injection, and the expression of p-STAT1 (B4) and TRAF3 (B5) decreased subsequently. However, p-NF-κB (B6), IL-6 (B7) and TNF-α (B8) increased significantly 3 days after GMH. The expression level of TRAF3 was significantly inhibited by its siRNA 3 days after intracerebroventricular injection, and p-NF-κB (C6), IL-6 (C7) and TNF-α (C8) maintained at high expression levels after declining of TRAF3 3 days after GMH.